Posted by Michael Wonder on 18 Nov 2020
HLS Therapeutics announces Health Canada approval of Perseris for the treatment of schizophrenia
17 November 2020 - First once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.
HLS Therapeutics announces that Health Canada has approved the use of Perseris (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults.
HLS has in-licensed the exclusive rights to Perseris for the Canadian market from Indivior.
